These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32469065)

  • 21. Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach.
    Vs R; D P; H M; P M; R A; S S; D D; I A; Z L; N A; A N; J K; R J; Sj B; M P; Dk M; M C; R N
    Indian J Hematol Blood Transfus; 2022 Apr; 38(2):223-234. PubMed ID: 35496970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful Treatment of Intracranial Methotrexate-associated Lymphoproliferative Disorder without Epstein-Barr Virus Infection Using Rituximab, Methotrexate, Procarbazine, and Vincristine: A Case Report.
    Mizushima M; Ishi Y; Ikeda H; Echizenya I; Otsuka T; Mitsuhashi T; Yamaguchi S; Fujimura M
    NMC Case Rep J; 2022; 9():237-242. PubMed ID: 36061907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose methotrexate dosing strategy in primary central nervous system lymphoma.
    Wang A; Cirrone F; De Los Reyes FA; Papadopoulos J; Saint Fleur-Lominy S; Xiang E
    Leuk Lymphoma; 2022 Jun; 63(6):1348-1355. PubMed ID: 35120432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.
    Schrum DP; Moorman MT; Li Z; Dillon M; Peters KB; McKinney M; Patel MP
    J Oncol Pharm Pract; 2024 Apr; 30(3):513-518. PubMed ID: 37198894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose methotrexate for elderly patients with primary CNS lymphoma.
    Zhu JJ; Gerstner ER; Engler DA; Mrugala MM; Nugent W; Nierenberg K; Hochberg FH; Betensky RA; Batchelor TT
    Neuro Oncol; 2009 Apr; 11(2):211-5. PubMed ID: 18757775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
    Suleman A; Liu J; Hicks LK; Drori AK; Crump M; Kridel R; Prica A; Berinstein N
    Haematologica; 2023 Apr; 108(4):1186-1189. PubMed ID: 36453110
    [No Abstract]   [Full Text] [Related]  

  • 27. Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
    Yuan X; Xie Y; Xu N; Liu H; Chen P; Zhao A; Liang Y; Qian W
    Haematologica; 2024 Jun; 109(6):2005-2009. PubMed ID: 38356447
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of upfront lenalidomide maintenance for primary central nervous system lymphoma following first-line methotrexate treatment: A retrospective study.
    Zhang Y; Wang W; Zhao D; Chong W; Chen C; Zhang W; Zhou D
    Cancer Med; 2024 May; 13(9):e7193. PubMed ID: 38738459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
    Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
    Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
    Han X; Ji Y; Ouyang M; Zhu T; Zhou D
    Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
    Zhong K; Shi Y; Gao Y; Zhang H; Zhang M; Zhang Q; Cen X; Xue M; Qin Y; Zhao Y; Zhang L; Liang R; Wang N; Xie Y; Yang Y; Liu A; Bao H; Wang J; Cao B; Zhang W; Zhang W
    BMC Cancer; 2023 Aug; 23(1):746. PubMed ID: 37568079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary Central Nervous System Lymphoma in a Patient with Down Syndrome.
    Shibata A; Yamaguchi F; Sasaki K; Yokobori S; Morita A
    J Nippon Med Sch; 2023 Sep; 90(4):346-350. PubMed ID: 35644559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.
    Tatarczuch M; Lewis KL; Gunjur A; Shaw B; Poon LM; Paul E; Ku M; Wong M; Ai S; Beekman A; Ciaccio PRD; Krigstein M; Wight J; Coombes C; Gilbertson M; Tey A; Shortt J; Nagarajan C; Talaulikar D; Hamad N; Ratnasingam S; Ho SJ; Cochrane T; Hawkes EA; Cheah CY; Opat S; Gregory GP
    EJHaem; 2024 Aug; 5(4):709-720. PubMed ID: 39157596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.
    Lurain K; Uldrick TS; Ramaswami R; Polizzotto MN; Goncalves PH; Widell A; Steinberg SM; Jaffe ES; Pittaluga S; Wang HW; Yuan CM; Tamula MA; Martin S; Wolters PL; George J; Little RF; Yarchoan R
    Blood; 2020 Nov; 136(19):2229-2232. PubMed ID: 32609814
    [No Abstract]   [Full Text] [Related]  

  • 35. Omission of etoposide in the treatment of haemophagocytic lymphohistiocytosis secondary to primary central nervous system lymphoma with satisfactory response.
    Laches R; Hall RJ; Chaffin J; Hahn P
    BMJ Case Rep; 2024 Jul; 17(7):. PubMed ID: 39002953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based expert consensus on the management of primary central nervous system lymphoma in China.
    Chen T; Liu Y; Wang Y; Chang Q; Wu J; Wang Z; Geng D; Yu JT; Li Y; Li XQ; Chen H; Zhuang D; Li J; Wang B; Jiang T; Lyu L; Song Y; Qiu X; Li W; Lin S; Zhang X; Lu D; Lei J; Chen Y; Mao Y
    J Hematol Oncol; 2022 Sep; 15(1):136. PubMed ID: 36176002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consolidation regimens in primary central nervous system lymphoma: a single-center retrospective cohort evaluating survival outcomes and cost-benefit analysis.
    Gelhard S; Maxwell A; Colman H; Cohen AL; Mendez JS
    J Neurooncol; 2022 Sep; 159(2):293-300. PubMed ID: 35764907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain radiotherapy in patients treated for a newly diagnosed primary central nervous system lymphoma: professional practice evaluation in 19 French centers.
    Thomas-Joulié A; Houillier C; Antoni D; Créhange G; Jouglar E; Colin P; Benchalal M; Lang P; Alfonsi M; Hamidou H; Coutte A; Ahrweiller F; Dadoun N; Pointreau Y; Ammarguellat H; Bernier-Chastagner V; Belkacemi Y; Vieillot S; Hoang-Xuan K; Soussain C; Jacob J; Feuvret L
    Acta Oncol; 2023 Jun; 62(6):648-656. PubMed ID: 37338525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.
    Yi JH; Kim SJ; Yang DH; Do YR; Won JH; Baek D; Shin HJ; Kim DS; Kim HJ; Kang KW; Bae SH; Kwon JH; Kwon JH; Park BB; Kim WS
    Br J Haematol; 2024 Aug; ():. PubMed ID: 39104032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].
    Sasaki N; Nagane M
    No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.